» Articles » PMID: 16765041

The Role of the Bone Microenvironment in the Pathophysiology and Therapeutic Management of Multiple Myeloma: Interplay of Growth Factors, Their Receptors and Stromal Interactions

Overview
Journal Eur J Cancer
Specialty Oncology
Date 2006 Jun 13
PMID 16765041
Citations 92
Authors
Affiliations
Soon will be listed here.
Abstract

The close relationship between the biological behaviour of malignant cells and the local microenvironment where they reside is a feature of diverse neoplasias. Multiple myeloma (MM) is considered a main disease model for the study of such interactions and the mechanisms that can lead to bone-related clinical complications, as well as the role of these interactions in attenuating the activity of conventional anti-MM therapeutics, such as dexamethasone and cytotoxic chemotherapeutics. This review focuses on recent progress in the study of interactions of MM cells with their local microenvironment. Major emphasis is placed on how bone marrow stromal cells (BMSCs) and other normal constituents of the bone marrow milieu promote, through cell adhesion- and cytokine-mediated mechanisms, the ability of MM cells to resist conventional anti-MM therapies. The review also addresses ongoing research into these mechanisms, which has already provided several new molecular targets and corresponding therapeutic strategies, such as the proteasome inhibitor bortezomib and thalidomide derivatives (e.g. lenalidomide), for the management of myeloma.

Citing Articles

TGF-β: an active participant in the immune and metabolic microenvironment of multiple myeloma : TGF-β in the microenvironment of multiple myeloma.

Xue H, Wei F Ann Hematol. 2024; 103(11):4351-4362.

PMID: 38900304 PMC: 11534828. DOI: 10.1007/s00277-024-05843-4.


Inhibition of VCP modulates NF-κB signaling pathway to suppress multiple myeloma cell proliferation and osteoclast differentiation.

Wei R, Cao Y, Wu H, Liu X, Jiang M, Luo X Aging (Albany NY). 2023; 15(16):8220-8236.

PMID: 37606987 PMC: 10497005. DOI: 10.18632/aging.204965.


In vivo bone marrow microenvironment siRNA delivery using lipid-polymer nanoparticles for multiple myeloma therapy.

Guimaraes P, Figueroa-Espada C, Riley R, Gong N, Xue L, Sewastianik T Proc Natl Acad Sci U S A. 2023; 120(25):e2215711120.

PMID: 37310997 PMC: 10288566. DOI: 10.1073/pnas.2215711120.


Past, Present, and a Glance into the Future of Multiple Myeloma Treatment.

Elbezanti W, Challagundla K, Jonnalagadda S, Budak-Alpdogan T, Pandey M Pharmaceuticals (Basel). 2023; 16(3).

PMID: 36986514 PMC: 10056051. DOI: 10.3390/ph16030415.


Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma.

Oudaert I, Van der Vreken A, Maes A, de Bruyne E, de Veirman K, Vanderkerken K Exp Hematol Oncol. 2022; 11(1):49.

PMID: 36050788 PMC: 9438316. DOI: 10.1186/s40164-022-00303-z.